Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(3.16)
# 1,571
Out of 5,176 analysts
46
Total ratings
45.83%
Success rate
93.34%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCOY Decoy Therapeutics | Initiates: Buy | $30 | $7.35 | +308.16% | 1 | Jan 23, 2026 | |
| NXTC NextCure | Upgrades: Buy | $18 | $10.19 | +76.64% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $11.70 | +28.21% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $1.73 | +998.27% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $11.61 | +158.40% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $3.66 | +501.09% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $7.70 | +211.69% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $16.67 | +649.85% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $2.86 | +529.37% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $1.99 | +854.77% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.41 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $153.22 | -48.33% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $104.91 | +47.75% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $29.49 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.18 | +686.16% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $3.70 | +48,548.65% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $31.44 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.58 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.68 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $2.95 | +50,747.46% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.20 | +74,900.00% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $9.34 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $11.78 | +1,300.68% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.68 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.75 | - | 2 | Jan 4, 2017 |
Decoy Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $30
Current: $7.35
Upside: +308.16%
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $10.19
Upside: +76.64%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $11.70
Upside: +28.21%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $1.73
Upside: +998.27%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $11.61
Upside: +158.40%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $3.66
Upside: +501.09%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $7.70
Upside: +211.69%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $16.67
Upside: +649.85%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $2.86
Upside: +529.37%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $1.99
Upside: +854.77%
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.41
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $153.22
Upside: -48.33%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $104.91
Upside: +47.75%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $29.49
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $3.18
Upside: +686.16%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $3.70
Upside: +48,548.65%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $31.44
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.58
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $4.68
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $2.95
Upside: +50,747.46%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.20
Upside: +74,900.00%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $9.34
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $11.78
Upside: +1,300.68%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $4.68
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.75
Upside: -